Navigation Links
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Date:11/28/2007

Company Plans to Initiate Phase III Program in First Half of 2008

LEXINGTON, Mass., Nov. 28 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced positive results from its Phase II octreotide implant trial in patients with acromegaly, a disorder characterized by excessive blood levels of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). The implant utilizes the Company's patented Hydron technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide that mimics the natural hormone somatostatin to block release of GH. In the recently completed six-month trial, the octreotide implant effectively suppressed levels of GH and IGF-1 at rates similar to those seen with current FDA approved injectable formulations of octreotide. In addition, the drug was well tolerated.

"I am extremely pleased to report the successful completion of our octreotide implant trial and we are looking forward to the initiation of our Phase III program in the first half of 2008," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The market opportunity for a six-month octreotide implant for the treatment of acromegaly is substantial. The results of the trial demonstrate the potential of our octreotide implant, the only once every six month treatment, to improve the treatment options for people who suffer from this life-long debilitating condition. In addition, based on the successful results of this trial, we are exploring opportunities to expand our octreotide development program to address other indications where injectable formulations of octreotide are currently utilized, including carcinoid tumors."

The trial w
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Stoltenberg Consulting , a ... announced the celebration of its 20-year anniversary and ... since its inception in 1995. ... the healthcare technology industry continues, we strive to ... to facilitating clients, organizational goals, understanding that today,s ...
(Date:6/2/2015)... 2, 2015 San MediTech, the industry leader ... monitoring (CGM) for diabetics, announced its plan to attend ... Boston on June 5 th ... Dynamic Glucose Monitoring System (DGMS). The company plans to ... the innovative technologies and advancements made by Chinese medical ...
(Date:6/2/2015)... June 2, 2015  PROMETRIKA, LLC, a full-service ... with the addition of pharmacovigilance services for clinical ... in safety data collection and reporting, as our ... professionals, and expert physicians, each with more than ... and monitoring of safety trends. ...
Breaking Medicine Technology:Stoltenberg Consulting celebrates 20 years of healthcare IT consulting service 2Stoltenberg Consulting celebrates 20 years of healthcare IT consulting service 3San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 2San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 3San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 4PROMETRIKA Announces the Availability of Pharmacovigilance Services 2
... 2012 Stereotaxis, Inc. (NASDAQ:   STXS) today ... European market the V-Sono™ intracardiac echocardiography manipulator module ... Designed to manipulate accessory devices such as variable ... Vdrive™ platform combines magnetic navigation with the Odyssey™ ...
... (NASDAQ: KERX ), a biopharmaceutical company focused ... pharmaceutical products for the treatment of renal disease (the ... ended March 31, 2012. At March 31, ... and investment securities of $31.0 million, as compared to ...
Cached Medicine Technology:Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 2Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 4
(Date:6/2/2015)... June 02, 2015 Did you wish Ryder ... to get him, his family isn’t asking for presents, but ... team walking in Saturday’s Cure HHT DC Walk. , Ryder ... that causes malformed blood vessels leading to sudden and extreme ... appear when Ryder was 3 years old in the form ...
(Date:6/2/2015)... On October 1, 2015 the transition to ICD-10 ... , On Monday, June 1st Congressman Kevin Brady, ... and Means Committee, and 12 members of the Committee ... Services, urging the administration to provide a smooth transition ... is the newest coding system for healthcare professionals to ...
(Date:6/2/2015)... Cochrane, Alberta (PRWEB) June 02, 2015 ... technology, announces the market entry of two new products ... and Kinomap Trainer announce new wireless interoperability in their ... training experience for cyclists. Tacx has implemented the FE-C ... trainer models as well as its new indoor training ...
(Date:6/2/2015)... 2015 ZOOM+, the Portland-based health innovator ... Insurance, announced today the opening of its on-demand ZOOM+Smile ... a three-in-one complete dental exam, cleaning and whitening in ... Like all ZOOM+ services, ZOOM+Smile can be scheduled by ... dentist office be as inviting as your favorite coffee ...
(Date:6/2/2015)... Mo. (PRWEB) June 02, 2015 With a ... Senior Living & Health Care has hired Leslie Young ... expansion of human resource initiatives to better understand and respond ... families in Tutera’s 47 communities in 13 states across the ... highest levels of personalized support to our residents, we are ...
Breaking Medicine News(10 mins):Health News:Six-Year-Old Walks to Bring Awareness to Genetic Disease 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 3Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 4
... Saing Ratha lies semi-conscious, her thin body shaking with fever as ... ice under her arms. ,Her 10-year-old bother Saing ... in this spartan rural clinic. ,Both have been struck ... in the first six months of this year as during the ...
... Thursday they will immunise 63 million children against measles in ... virulent disease is one of the deadliest threats to young ... day, but vaccination coverage here is currently only 69 percent. ... world. I think it will show a lot of results," ...
... Scientists of the Department of Personality, Evaluation and Psychological ... have studied how some psychological variables such as ... are related to sexual desire in human beings. ... there are very few reliable and valid instruments in ...
... men and women with multiple sclerosis (MS) equally transmit the ... ,The research contradicts the findings of a recent study, ... to transmit the risk of developing MS to their children. ... affected with MS. Of the 8,401 children in those families, ...
... harried by the super bug Clostridium difficile (C diff), good news ... the hospital infection, researchers say. ,Clostridium difficile (C. ... of around 3% of adults and 66% of children. ... antibiotics that are used to treat other health conditions can interfere ...
... than 2% incontinence are the striking results of a ... innovative treatment for prostate cancer. HDR (high dose ... technology was shown to be just as effective as ... common side-effects of impotence and incontinence. ,Conventional Therapy ...
Cached Medicine News:Health News:Dengue Deaths Sweeping Cambodia Highlight Healthcare Failures 2Health News:Dengue Deaths Sweeping Cambodia Highlight Healthcare Failures 3Health News:Pakistan to Launch World's Biggest Anti-measles Drive 2Health News:Sexual Fantasies Play an Important Role in Boosting Desire 2Health News:Sexual Fantasies Play an Important Role in Boosting Desire 3Health News:Probiotic Drinks can Stave Off Hospital Infection 2Health News:Impotence and Incontinence Greatly Reduced With New Prostate Cancer Treatment 2Health News:Impotence and Incontinence Greatly Reduced With New Prostate Cancer Treatment 3Health News:Impotence and Incontinence Greatly Reduced With New Prostate Cancer Treatment 4
The Closer vascular closure device is a suture mediated closure system. It has a sheath-like profile and easy positioning. It has an innovative design which involves the needles outside the artery an...
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
These are coronary angiographic catheters used for selective coronary bypass angiography. The catheters curve configuration is ideally suited to select the internal mammary artery....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: